Roche Licenses Hanmi’s Muscle-Sparing Obesity Drug
August 25, 2026
Roche’s Genentech will pay $190 million upfront for global rights to Hanmi’s experimental obesity drug HM17321.
Ambros and Werewolf Agree $550M Reverse Merger
August 25, 2026
Ambros Therapeutics will merge with Werewolf and raise $150 million to advance neridronate for complex regional pain syndrome.
Network Bio Launches with $50M Financing
August 21, 2026
Network Bio launched with $50 million to build AI models from patient tissues, blood samples and linked clinical outcomes.
BlueRock Automates Cell Therapy Analytics
August 20, 2026
BlueRock Therapeutics developed an automated system to audit cell therapy products using small samples and high-throughput testing.
Merck and Moderna Score Phase 3 Vaccine Success
August 20, 2026
Merck and Moderna’s personalised mRNA neoantigen therapy improved recurrence-free and distant metastasis-free survival in melanoma.
BioMarin to Acquire Alesta for Oral HPP Drug
August 20, 2026
BioMarin will acquire Alesta and its oral HPP candidate ALE1 for $275 million upfront plus up to $215 million in milestones.
Leica Biosystems to Acquire StatLab Medical Products
July 21, 2026
Leica Biosystems agreed to acquire StatLab to expand Danaher’s diagnostics and pathology footprint.
Circio and Avenue Biosciences Team up on Engineered circRNA
July 21, 2026
Circio and Avenue Biosciences will combine circVec and protein engineering to improve secreted protein expression in gene therapy.
Cellares and Papillon Partner to Automate PPL-001 Manufacturing
July 21, 2026
Cellares and Papillon Therapeutics will automate manufacturing of PPL-001, a gene-corrected stem cell therapy for Friedreich’s ataxia.
AdvanCell Raises $315 Million for Pluvicto Challenger Buildout
July 16, 2026
AdvanCell raised $315 million to advance a prostate cancer radiopharmaceutical and build U.S. manufacturing capacity.
AstraZeneca Licenses Dizal’s EGFR Exon 20 Lung Cancer Drug
July 16, 2026
AstraZeneca will license global rights to Dizal’s Zegfrovy in a deal worth up to $1.5 billion for EGFR exon 20 NSCLC.
Celcuity Wins FDA Approval for Revtorpyk
July 16, 2026
Celcuity won FDA approval for Revtorpyk in HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation.
Cellares and Sonoma Biotherapeutics Automate SBT-77-7101
July 14, 2026
Cellares and Sonoma Biotherapeutics will automate manufacturing of SBT-77-7101, a Treg therapy for rheumatoid arthritis.
Insilico and China Medical System Expand CNS Push
July 13, 2026
Insilico and China Medical System signed a 1.2 billion yuan deal to develop a mass-market CNS indication.
AstraZeneca Licences China COPD Molecule
July 13, 2026
AstraZeneca has licensed a Sino Biopharmaceutical COPD candidate with dual action in a deal aimed at respiratory pipeline growth.